Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe

... HITCHIN England and SAN DIEGO Sept. 27 /- Flynn Ph...(Logo: A HREF http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOG...Pacira Pharmaceuticals a former business unit of SkyePharma PLC is...DepoDur which utilizes the DepoFoam technology is a novel singledo...

HITCHIN, England, and SAN DIEGO, Sept. 27 /PRNewswire/ -- Flynn Pharma
Limited, a specialty pharmaceutical company focused on acquiring and
commercializing proprietary products in secondary healthcare and related
markets, today announced it has acquired exclusive marketing and
distribution rights to DepoDur(R) (morphine sulphate extended release
liposome injection) for Europe and a number of other markets from San
Diego-based Pacira Pharmaceuticals.

Pacira Pharmaceuticals, a former business unit of SkyePharma, PLC, is
an independent private company focused on developing and manufacturing
controlled-release injectable products based on their DepoFoam(R) and
Biosphere(R) drug delivery platforms.

DepoDur, which utilizes the DepoFoam technology, is a novel, single
dose extended-release formulation of morphine. A single injection of
DepoDur into the lumbar epidural space may provide pain relief for up to 48
hours following major surgery without the restrictions and potential
complications associated with an indwelling epidural catheter. DepoDur is
the only opioid approved in Europe (UK, MHRA, 2006) for epidural use. In
the US, DepoDur is marketed by EKR Therapeutics, Inc.

"We are pleased to add an innovative product like DepoDur to our
growing hospital product portfolio." said David Walters, Director of Flynn.
"DepoDur is consistent with, and complementary to, our model of adding
products for the secondary healthcare markets."

Fred Middleton, Pacira's Chairman of the Board commented, "In DepoDur,
Flynn Pharma will have a new foundation on which to continue building their
hospital franchise. Through the use of Pacira's extended-release injectable
technology, DepoFoam, DepoDur supports the sustained release of epidural
morphine to provide up to 48 hours of post-surgery pain relief, when most
pain can then be satisfactorily controlled with oral analgesics. In
addition, there are an estimated 5 million surgical procedures in Europe
where DepoDur can be used to manage post-operative pain in hospitalised
patients. With a proven technology, a large market opportunity, and Flynn's
strong presence in hospitals, we look forward to having Flynn as our
commercial marketing partner expanding DepoDur's use into Europe."

David Walters further noted, "Flynn is starting the launch process,
including meetings with key opinion leaders, and we expect to have our UK
sales force fully supporting DepoDur early in 2008." He concluded, "We are
very optimistic about Flynn's growth prospects in 2008 and beyond as we
plan DepoDur's market penetration in Europe. We are actively planning to
take the product beyond the UK through the mutual recognition procedure and
have initiated the search and selection of marketing partners in Europe.
This is the second new product Flynn will have launched into the hospital
market following the successful launch of Medikinet(R) XL in March 2007."

About Flynn Pharma Limited

Flynn Pharma focuses on the acquisition, development and
commercialisation of proprietary products for the secondary healthcare and
related markets, including oncology and CNS therapeutics. Flynn's goal is
to be the foremost European provider of specialty products in these
targeted and underserved therapeutic categories. In the last few years,
Flynn has been restructured and financed to pursue an aggressive and rapid
growth strategy in these sectors, offering superior customer service and
value growth for our shareholders. For additional information about Flynn
visit the Company's website at http://www.flynnpharma.com.

About Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a wholly owned subsidiary of Pacira
Inc., a Delaware corporation, which is controlled and funded by a group of
financial investors including Sanderling Ventures, HBM Bioventures (Cayman)
Ltd, OrbiMed Advisors, and MPM Capital. This business is based in San
Diego, CA, and focuses on formulating, developing and manufacturing
controlled-release injectable products based on two proprietary drug
delivery platforms: DepoFoam(R) and Biosphere(R). Revenues are generated
from two marketed products: DepoCyt(R) for lymphomatous meningitis and
DepoDur(R) for the treatment of post-surgical pain. For additional
information about Pacira visit the Company's website at
http://www.pacira.com

(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...

(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...

(Date:10/11/2017)... 2017 True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...

(Date:10/7/2017)... , Oct. 6, 2017 Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...